Trial · NCT02912364

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

NCT02912364, Phase 4, Completed, Stanford University; results first posted 2019-06-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults. Trials, record NCT02912364. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02912364

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults
NCT number: NCT02912364
Status: Completed
Phases: Phase 4
Enrollment: 46 participants, actual
Lead sponsor: Stanford University
Conditions: Epilepsy
Interventions: Eslicarbazepine, Carbamazepine
First posted: 2016-09-23
Last updated: 2019-06-04
Results first posted: 2019-06-04

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Composite Z Score of Neuropsychological Battery as a Measure of Direct Comparison of the 2 Antiepileptic Drugs.	At the end of each 6-week drug treatment period.	Z score of cognitive tests at end of each 6-week drug treatment period for each intervention (i.e., Eslicarbazepine and Carbamazepine). The Z-score indicates the number of standard deviations away from a reference population. A Z-score of 0 is equal to the mean. Negative numbers indicate poor cognitive performance compared to the mean and positive numbers represent higher cognitive performance compared to the mean.
Secondary	Overall Z-score for Executive Function.	At the end of each 6-week drug treatment period.	Executive function consists of a composite of measures from the computerized cognitive tests. The Z-score indicates the number of standard deviations away from a reference population. A Z-score of 0 is equal to the mean. Negative numbers indicate poor cognitive performance compared to the mean and positive numbers represent higher cognitive performance compared to the mean.
Secondary	MCG Paragraph Recall Scores.	Prior to treatment (non-drug condition average) and at the end of each six-week treatment period.	Participants were read a paragraph and were asked to recall content immediately following and twenty minutes after hearing the reading. MCG = Medical College of Georgia. Assessments were performed prior to treatment (non-drug condition average) and at the end of each treatment period. Score range: 0 - 60, higher scores indicate better memory function.
Secondary	Dual Task Percent of Time in Box.	Prior to treatment (non-drug condition average) and at the end of each six-week treatment period.	Participants were asked to use their computer mouse to keep the cursor inside a moving box on the computer screen while simultaneously responding with a button press when a number on the screen exceeded a certain value. Assessments were performed prior to treatment (non-drug condition average) and at the end of each treatment period.
Secondary	Profile of Mood States (POMS) Score.	Prior to treatment (non-drug condition average) and at the end of each six-week treatment period.	Participants were asked to rate the extent to which they feel a variety of emotions/feelings. The overall score is presented. Assessments were performed prior to treatment (non-drug condition average) and at the end of each treatment period. Score range: -32 to 200. Lower scores correspond to better mood state.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Composite Z Score of Neuropsychological Battery as a Measure of Direct Comparison of the 2 Antiepileptic Drugs.	At the end of each 6-week drug treatment period.	Participants who completed the protocol are included in the analysis. That is, participants who completed both treatment arms (completed treatment 2 in the participant flow) are included in the analysis.	Z-score	MEAN
SECONDARY	Overall Z-score for Executive Function.	At the end of each 6-week drug treatment period.	Participants who completed the protocol are included in the analysis. That is, participants who completed both treatment arms (Eslicarbazepine and Carbamazepine) are included in the analysis.	Z-score	MEAN
SECONDARY	MCG Paragraph Recall Scores.	Prior to treatment (non-drug condition average) and at the end of each six-week treatment period.	Participants who completed the protocol are included in the analysis. That is, participants who completed both treatment arms (Eslicarbazepine and Carbamazepine) are included in the analysis.	units on a scale	MEAN
SECONDARY	Dual Task Percent of Time in Box.	Prior to treatment (non-drug condition average) and at the end of each six-week treatment period.	Participants who completed the protocol are included in the analysis. That is, participants who completed both treatment arms (Eslicarbazepine and Carbamazepine) are included in the analysis.	percentage of time in box	MEAN
SECONDARY	Profile of Mood States (POMS) Score.	Prior to treatment (non-drug condition average) and at the end of each six-week treatment period.	Participants who completed the protocol are included in the analysis. That is, participants who completed both treatment arms (Eslicarbazepine and Carbamazepine) are included in the analysis.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall Composite Z Score of Neuropsychological Battery as a Measure of Direct Comparison of the 2 Antiepileptic Drugs.	Eslicarbazepine		.001	Standard Deviation .50	Z-score
Overall Composite Z Score of Neuropsychological Battery as a Measure of Direct Comparison of the 2 Antiepileptic Drugs.	Carbamazepine		-.23	Standard Deviation .61	Z-score
Overall Z-score for Executive Function.	Eslicarbazepine		.22	Standard Deviation .53	Z-score
Overall Z-score for Executive Function.	Carbamazepine		-.32	Standard Deviation .76	Z-score
MCG Paragraph Recall Scores.	Non-drug Condition Average	Immediate Recall	34	Standard Deviation 17	units on a scale
MCG Paragraph Recall Scores.	Eslicarbazepine	Immediate Recall	33	Standard Deviation 12	units on a scale
MCG Paragraph Recall Scores.	Carbamazepine	Immediate Recall	31	Standard Deviation 15	units on a scale
MCG Paragraph Recall Scores.	Non-drug Condition Average	Delayed Recall	33	Standard Deviation 18	units on a scale
MCG Paragraph Recall Scores.	Eslicarbazepine	Delayed Recall	31	Standard Deviation 13	units on a scale
MCG Paragraph Recall Scores.	Carbamazepine	Delayed Recall	30	Standard Deviation 16	units on a scale

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow22

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Treatment 1	STARTED	Eslicarbazepine, Then Carbamazepine	23
Treatment 1	STARTED	Carbamazepine, Then Eslicarbazepine	23
Treatment 1	Received Intervention	Eslicarbazepine, Then Carbamazepine	18
Treatment 1	Received Intervention	Carbamazepine, Then Eslicarbazepine	18
Treatment 1	COMPLETED	Eslicarbazepine, Then Carbamazepine	13
Treatment 1	COMPLETED	Carbamazepine, Then Eslicarbazepine	11
Treatment 1	NOT COMPLETED	Eslicarbazepine, Then Carbamazepine	10
Treatment 1	NOT COMPLETED	Carbamazepine, Then Eslicarbazepine	12
Washout Period	STARTED	Eslicarbazepine, Then Carbamazepine	13
Washout Period	STARTED	Carbamazepine, Then Eslicarbazepine	11

1 to 10 of 22Source ClinicalTrials.gov

See all 22 participant flow

Adverse events56

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Agitation	Nervous system disorders	Eslicarbazepine	0	29
other	Agitation	Nervous system disorders	Carbamazepine	1	30
other	Altered pitch perception (pitch seemed lower)	Nervous system disorders	Eslicarbazepine	0	29
other	Altered pitch perception (pitch seemed lower)	Nervous system disorders	Carbamazepine	1	30
other	Clouded vision	Nervous system disorders	Eslicarbazepine	1	29
other	Clouded vision	Nervous system disorders	Carbamazepine	0	30
other	Constipation	Gastrointestinal disorders	Eslicarbazepine	1	29
other	Constipation	Gastrointestinal disorders	Carbamazepine	1	30
other	Coordination/balance problems	Nervous system disorders	Eslicarbazepine	0	29
other	Coordination/balance problems	Nervous system disorders	Carbamazepine	1	30

1 to 10 of 56Source ClinicalTrials.gov

See all 56 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Eslicarbazepine	0	29
Total, all-cause mortality	Carbamazepine	0	30
Total, other adverse events	Eslicarbazepine	12	29
Total, other adverse events	Carbamazepine	21	30
Total, serious adverse events	Eslicarbazepine	0	29
Total, serious adverse events	Carbamazepine	0	30

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Eslicarbazepine vs Carbamazepine: deaths from any cause	Trial comparisons
Eslicarbazepine vs Carbamazepine: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02912364

GET https://conductscience.org/api/trials/v1/NCT02912364/flow?page=2

API reference For AI assistants